­MetrioPharm: Sven Zimmermann joins as CFO

MetrioPharm AG, a pharmaceutical development company, welcomes Sven Zimmermann, as its new Chief Financial Officer, bringing more than a decade of experience in strategic transactions.

Sven Zimmermann holds a doctorate in molecular biology and initially worked as an analyst for the European biotech sector at UBS in Zurich and London. He has extensive experience in corporate finance and capital raising and has worked on five successful exits. Most recently, as CFO of Novimmune SA, he helped with the sale of the company’s main asset to the Swedish Sobi AB for CHF 515 million.

In 2010, he supported the sale of PregLem SA to the Hungarian Gedeon Richter for CHF 445 million and, in 2014, the IPO of Auris Medical AG on NASDAQ. As a member of the Board of Directors of Aimago AG and Epiontis GmbH, he was also involved in the sales of these companies.

Rudolf Stäger, Chairman of the Board of Directors of MetrioPharm AG: "Sven Zimmermann is our ideal candidate for the position of CFO. He has worked successfully in the healthcare sector for many years. He will contribute great expertise in the operational business as well as an excellent personal network. In addition to his business know-how, he will also be able to provide scientific expertise, especially in the field of immunology and inflammatory diseases".

Sven Zimmermann: "I look forward to supporting the Board of Directors and the shareholders of MetrioPharm AG in successfully implementing the corporate strategy. The company has made impressive progress over the past years and now it is important to tap this potential in the best possible and sustainable way".